“With the full results of RMCL-002 to be presented at the European Renal Association Congress later this month and the upcoming interim readout of REGEN-007 in mid-2024, we look forward to further elucidating the effect of rilparencel in preserving kidney function in patients with type 2 diabetes and CKD,” said Bruce Culleton, Chief Executive Officer. “I believe our recent hires of Dr. Ulrich Ernst and Lucio Tozzi will prove invaluable in the execution of our planned manufacturing and Phase 3 study milestones. With our PROACT 1 protocol amendment completed and submitted to the FDA, we look forward to the resumption of the study as we focus on patients with severe CKD. Rilparencel has the potential to be meaningful in this high-risk patient population where there are limited therapeutic options for care.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PROK:
- ProKidney Reports Business Updates and First Quarter 2024 Financial Results
- ProKidney Bolsters Leadership with Expert EVP, Enhances Operations
- ProKidney appoints Ulrich Ernst as EVP, technical operations
- ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
- ProKidney reports FY23 EPS (57c), consensus (65c)